Survivin Inhibitors Mitigate Chemotherapeutic Resistance in Breast Cancer Cells by Suppressing Genotoxic Nuclear Factor-κB Activation
Open Access
- 1 July 2018
- journal article
- research article
- Published by Elsevier in The Journal of Pharmacology and Experimental Therapeutics
- Vol. 366 (1) , 184-193
Abstract
Therapeutic resistance developed after chemotherapy and aggressive metastasis are the major causes of cancer-related death in patients with triple-negative breast cancer (TNBC). Survivin is the smallest member of the inhibitor-of-apoptosis proteins (IAPs) family, which plays critical roles in cell division and cell survival. High expression levels of survivin have been associated with therapeutic resistance in various cancers. We recently developed a novel small-molecule survivin inhibitor mimicking the IAP-binding motif of second mitochondria-derived activator of caspase, which showed high potency in promoting survivin degradation. Here, we show that survivin inhibitor MX106/MX107 suppresses TNBC cell proliferation. Moreover, MX106/MX107 synergized with chemotherapeutic drugs or radiation and significantly enhanced tumoricidal efficacy of genotoxic treatments. Mechanistically, MX106/MX107 induced degradation of XIAP and/or cIAP1, which inhibited nuclear factor κB (NF-κB) activation by genotoxic agents. Treatment with MX106/MX107 alone did not activate alternative NF-κB signaling in breast cancer cells, which is likely attributable to their selective potency in degrading survivin in these cells. In addition, survivin degradation by MX106/MX107 dramatically increased abnormal mitotic spindle formation and cell division failure, which led to cell cycle arrest in breast cancer cells. Overall, our study suggests that combination treatment of TNBC using survivin inhibitors MX106/MX107 with cytotoxic chemotherapeutic drugs can achieve significantly improved therapeutic efficacy, which depends on MX106/MX107-mediated inhibition of genotoxic NF-κB activation.Keywords
This publication has 47 references indexed in Scilit:
- Survivin – The inconvenient IAPSeminars in Cell & Developmental Biology, 2015
- Discovery of Novel Second Mitochondria-Derived Activator of Caspase Mimetics as Selective Inhibitor of Apoptosis Protein InhibitorsThe Journal of Pharmacology and Experimental Therapeutics, 2014
- Treat cancers by targeting survivin: Just a dream or future reality?Cancer Treatment Reviews, 2013
- Sticky siRNAs targeting survivin and cyclin B1 exert an antitumoral effect on melanoma subcutaneous xenografts and lung metastasesBMC Cancer, 2013
- Mitotic catastrophe: a mechanism for avoiding genomic instabilityNature Reviews Molecular Cell Biology, 2011
- Triple-Negative Breast CancerNew England Journal of Medicine, 2010
- A Cytoplasmic ATM-TRAF6-cIAP1 Module Links Nuclear DNA Damage Signaling to Ubiquitin-Mediated NF-κB ActivationMolecular Cell, 2010
- EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancerOncogene, 2010
- Molecular Linkage Between the Kinase ATM and NF-κB Signaling in Response to Genotoxic StimuliScience, 2006
- Nuclear factor-κB inhibitors as sensitizers to anticancer drugsNature Reviews Cancer, 2005